Lung Cancer (NSCLC): Expanded Access For Lorlatinib For Patients With Non Small Cell
Lung Cancer Carrying an ALK or ROS1 Rearrangement
There is no research question. This is an expanded access program.
Basic Study Information
Purpose:Location: Cancer Center
This is an expanded access program. The program is sponsored by the pharmaceutical
company named Pfizer, Inc. (the "Sponsor"). The purpose of this program is to allow
patients with advanced non-small cell lung cancer access to lorlatinib treatment and
to find out the good and bad effects of this drug.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03178071?term=B7461020&rank=1
Study Reference #: ELUN17127
Lead Researcher (Principal Investigator)
Lead Researcher: Deborah Mulford, MD
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Learn More About These Conditions
More information about Lung Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search